Generation Bio is a biotechnology company changing what is possible for people living with T cell-driven autoimmune diseases. The company is developing a new modality of therapeutics leveraging its T cell selective cell-targeted lipid nanoparticle (ctLNP) to deliver siRNA in vivo, enabling modulation of T cell activity that causes inflammation and auto-reactive tissue destruction.
| Website | http://www.generationbio.com |
| Revenue | $13.2 million |
| Employees | 85 (85 on RocketReach) |
| Founded | 2016 |
| Address | 301 Binney Street 4th Floor, Cambridge, Massachusetts 02142, US |
| Technologies |
JavaScript
,
HTML
,
PHP
+51 more
(view full list)
|
| Industry | Biotechnology Research, Biotechnology, Rare Disease, Cedna Gene Therapy |
| Keywords | Rare Diseases, Gene Therapy, Dna Therapeutics, Innovative Therapies, Pharmaceutical Research, Biotechnology, Clinical Trials, Drug Development, Life Sciences, Healthcare, Medical Research, Therapeutics, Biopharma |
| Competitors | Audentes Therapeutics, CRISPR Therapeutics, CureVac, Spark Therapeutics, Inc., bluebird bio, Abeona Therapeutics, Intellia Therapeutics, Inc., Beam Therapeutics, Scribetx, Editas Medicine +39 more (view full list) |
Looking for a particular Generation Bio employee's phone or email?
Generation Bio Questions
The Generation Bio annual revenue was $13.2 million in 2026.
Yalonda Howze is the Interim Chief Executive Officer and President of Generation Bio.
85 people are employed at Generation Bio.
Generation Bio is based in Cambridge, Massachusetts.
Top Generation Bio Employees
-
14
-
Nathaniel Silver
SVP Preclinical Research at Generation Bio
Cambridge, MA, US22 -
Russell Monds
Vice President of Molecular Biology at Generation Bio
Cambridge, MA, US24 -
35
-
Di Bush
VP, Head of Delivery at Generation Bio
Arlington, MA, US13
Related Companies
